Advanced search
Publication Cover
Leukemia & Lymphoma Volume 64, 2023 - Issue 4
Submit an article Journal homepage
137
Views
0
CrossRef citations to date
0
Altmetric
Letters to the Editor

Palpable spleen size is differently prognostic in primary and secondary myelofibrosis

Marko Lucijanica Hematology Department, University Hospital Dubrava, Zagreb, Croatia;b University of Zagreb School of Medicine, Zagreb, CroatiaCorrespondence[email protected]
ORCID Iconhttps://orcid.org/0000-0002-1372-2040
ORCID Icon,
Ivan Krecakc Department of Internal Medicine, General Hospital Sibenik, Sibenik, Croatia;d University of Rijeka School of Medicine, RijekaORCID Iconhttps://orcid.org/0000-0002-8642-305X
ORCID Icon,
Ena Sorica Hematology Department, University Hospital Dubrava, Zagreb, Croatia
,
Davor Galusice Department of Hematology, University Hospital of Split, Split, Croatia;f University of Split School of Medicine, Split, Croatia
,
Hrvoje Holikg Department of Internal Medicine, “Dr. Josip Bencevic” General Hospital, Ul. Andrije Stampara, Slavonski Brod, Croatia;h University of Osijek Faculty of Medicine, Osijek, Croatia
,
Vlatka Perisah University of Osijek Faculty of Medicine, Osijek, Croatia;i Department of Hematology, Osijek University Hospital, Osijek, Croatia
,
Martina Moric Pericj Department of Internal Medicine, General Hospital Zadar, Zadar, Croatia
,
Ivan Zekanovicj Department of Internal Medicine, General Hospital Zadar, Zadar, Croatia
&
Rajko Kuseca Hematology Department, University Hospital Dubrava, Zagreb, Croatia;b University of Zagreb School of Medicine, Zagreb, Croatia
 show all
Pages 893-896 | Received 10 May 2022, Accepted 05 Feb 2023, Published online: 17 Feb 2023

References

  • Song MK, Park BB, Uhm JE. Understanding splenomegaly in myelofibrosis: association with molecular pathogenesis. Int J Mol Sci. 2018;19(3):898.
  • Song MK, Chung JS, Lim SN, et al. Usefulness of spleen volume measured by computed tomography for predicting clinical outcome in primary myelofibrosis. Int J Hematol. 2016;104(4):476–484.
  • Randhawa J, Ostojic A, Vrhovac R, et al. Splenomegaly in myelofibrosis–new options for therapy and the therapeutic potential of Janus kinase 2 inhibitors. J Hematol Oncol. 2012;5:43.
  • Courtier F, Garnier S, Carbuccia N, et al. Targeted molecular characterization shows differences between primary and secondary myelofibrosis. Genes Chromosomes Cancer. 2020;59(1):30–39.
  • Lucijanic M, Krecak I, Soric E, et al. Patients with post polycythemia vera myelofibrosis might experience increased thrombotic risk in comparison to primary and post essential thrombocythemia myelofibrosis. Leuk Res. 2022;119:106905.
  • Passamonti F, Cervantes F, Vannucchi AM, et al. A dynamic prognostic model to predict survival in primary myelofibrosis: a study by the IWG-MRT (International Working Group for Myeloproliferative Neoplasms Research and Treatment). Blood. 2010;115(9):1703–1708.
  • Passamonti F, Giorgino T, Mora B, et al. A clinical-molecular prognostic model to predict survival in patients with post polycythemia vera and post essential thrombocythemia myelofibrosis. Leukemia. 2017;31(12):2726–2731.
  • Palandri F, Palumbo GA, Bonifacio M, et al. Baseline factors associated with response to ruxolitinib: an independent study on 408 patients with myelofibrosis. Oncotarget. 2017;8(45):79073–79086.
  • Maffioli M, Mora B, Ball S, et al. A prognostic model to predict survival after 6 months of ruxolitinib in patients with myelofibrosis. Blood Adv. 2022;6(6):1855–1864.
  • Arber DA, Orazi A, Hasserjian R, et al. The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia. Blood. 2016;127(20):2391–2405.
  • Barosi G, Mesa RA, Thiele J, et al. Proposed criteria for the diagnosis of post-polycythemia vera and post-essential thrombocythemia myelofibrosis: a consensus statement from the International working group for myelofibrosis research and treatment. Leukemia. 2008;22(2):437–438.
  • Barosi G, Bergamaschi G, Marchetti M, , et al. JAK2 V617F mutational status predicts progression to large splenomegaly and leukemic transformation in primary myelofibrosis. Blood. 2007;110(12):4030–4036.
  • Rumi E, Pietra D, Pascutto C, et al. Clinical effect of driver mutations of JAK2, CALR, or MPL in primary myelofibrosis. Blood. 2014;124(7):1062–1069.
  • Bazdaric K, Sverko D, Salaric I, et al. The ABC of linear regression analysis: what every author and editor should know. ESE. 2021;47:e63780.
  • Lucijanić M. Survival analysis in clinical practice: analyze your own data using an excel workbook. Croat Med J. 2016;57(1):77–79.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.